NCT03829878View on ClinicalTrials.gov

Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

May 31, 2020

Primary Completion Date

May 31, 2020

Study Completion Date

December 31, 2021

Conditions
Autism Spectrum DisorderAutismASDAutistic ThinkingAutistic BehaviorFinchFMTFecal Microbiota TransplantCP101SPROUTFecal Transplant
Interventions
DRUG

CP101

Orally administered donor derived full spectrum microbiota

DRUG

Placebo

Placebo for CP101

Sponsors
All Listed Sponsors
lead

Finch Research and Development LLC.

INDUSTRY

NCT03829878 - Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT) | Biotech Hunter | Biotech Hunter